** Shares of Solid Biosciences SLDB.O rises 51.9% to $6.12
** Co says its experimental gene therapy for a rare muscle wasting disorder was well-tolerated in 6 participants dosed in an early-stage study
** Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, which interferes with the production of proteins needed to form healthy muscles
** Says no serious adverse events were observed
** Also says that some patients showed significant improvements in multiple muscle health biomarkers
** Separately, co's 35.7 mln stock offering priced at $4.03 each, which was the last closing price of its shares
** SLDB has fallen ~56% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。